Summary of Product Characteristics Updated 22-Jul-2019 | Merus Labs Luxco II S.à R.L.
Isoket Retard 40 Tablets
Each tablet contains isosorbide dinitrate 40 mg in a prolonged release formulation.
Excipients with known effect: 162.70 mg lactose monohydrate
For the full list of excipients, see section 6.1.
Prolonged release tablets.
White with break score, marked IR 40 on the upper side and with SCHWARZ PHARMA on the reverse side.
For the prophylaxis and treatment of angina pectoris.
Adults: One tablet to be taken once daily without chewing and with a sufficient amount of fluid. For patients with higher nitrate requirements the dose may be increased to one tablet twice daily; but ensuring a 12 hours treatment free interval every 24 hours.
Elderly population: Clinical experience has not necessitated alternative advice for use in elderly patients.
Paediatric population: The safety and efficacy of Isoket Retard has yet to be established.
Method of administration
For oral administration
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
This product should not be given to patients with a known sensitivity to nitrates, very low blood pressure, acute myocardial infarction with low filling pressure, marked anaemia, head trauma, cerebral haemorrhage, acute circulatory failure, severe hypotension or hypovolaemia.
Phosphodiesterase inhibitors (e.g. Sildenafil) have been shown to potentiate the hypotensive effects of nitrates, and their co-administration with nitrates or nitric oxide donors is therefore contraindicated.
During nitrate therapy, the soluble guanylate cyclase stimulator riociguat must not be used (see section 4.5).
These tablets should be used with caution in patients who are suffering from hypothyroidism, hypothermia, malnutrition, severe liver disease or renal disease.
Symptoms of circulatory collapse may arise after the first dose, particularly in patients with labile circulation.
This product may give rise to symptoms of postural hypotension and syncope in some patients.
These tablets should be used with particular caution and under medical supervision in the following:
Hypertrophic obstructive cardiomyopathy (HOCM), constrictive pericarditis, cardiac tamponade, low cardiac filling pressures, aortic/mitral valve stenosis, and diseases associated with raised intracranial pressure.
Treatment with these tablets must not be interrupted or stopped to take phosphodiestearase inhibitors due to the increased risk of inducing an attack of angina pectoris.
If these tablets are not taken as indicated with the appropriate dosing interval (see section 4.2) tolerance to the medication could develop.
Caution should be exercised in patients with hypoxaemia and ventilation/perfusion imbalance due to lung disease or ischaemic heart failure. As a potent vasodilator, ISDN could result in increased perfusion of poorly ventilated areas, worsening of the ventilation/perfusion imbalance, and a further decrease in the arterial partial pressure of oxygen.
During treatment with ISDN alcohol should be avoided as it may potentiate the hypotensive and vasodilating effect of ISDN (see section 4.5).
Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Concurrent intake of drugs with blood pressure lowering properties e.g. beta blockers, calcium antagonists, vasodilators, ACE-inhibitors, monoamine oxidase inhibitors etc. and/or alcohol may potentiate the hypotensive effect of the tablets. Symptoms of circulatory collapse can arise in patients already taking ACE inhibitors.
The concurrent intake of ISDN with ACE-inhibitors or arterial vasodilators could be a desirable interaction unless the antihypertensive effects are excessive in which case consider reducing the dose of one or both drugs.
The hypotensive effect of nitrates is potentiated by concurrent administration of phosphodiesterase inhibitors (e.g. sildenafil). This might also occur with neuroleptics and tricyclic antidepressants.
Reports suggest that when administered concomitantly, nitrates may increase the blood level of dihydroergotamine and its hypertensive effect.
Saproterin (Tetrahydrobioterine, BH4) is a cofactor for nitric oxide sythetase. Caution is recommended during concomitant use of saproterin-containing medicine with all agents that cause vasodilation by affecting nitric oxide (NO) metabolism or action, including classical NO donors (e.g. glyceryl trinitrate (GTN), isosorbide dinitrate (ISDN), isosorbide mononitrate (ISMN) and others).
The use of isosorbide dinitrate with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see section 4.3) since concomitant use can cause hypotension.
Pregnancy and lactation
This product should not be used during pregnancy or lactation unless considered essential by the physician.
There is no data available on the effect of ISDN on fertility in humans.
Headaches, tiredness and dizziness may occur. These may affect the ability to drive and operate machinery. Patients should not drive or operate machinery if their ability is impaired.
Undesirable effects frequencies are defined as: very common (≥1/10), common (≥1/100,<1/10), uncommon (≥1/1,000,<1/100), rare ≥1/10,000,<1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
During administration of Isoket the following undesirable effects may be observed:
Nervous system disorders:
Very common: headache
Common: dizziness, somnolence
Uncommon: angina pectoris aggravated
Common: orthostatic hypotension
Uncommon: circulatory collapse (sometimes accompanied by bradyarrhythmia and syncope)
Not known: hypotension
Uncommon: nausea, vomiting
Very rare: heartburn
Skin and subcutaneous tissue disorders:
Uncommon: allergic skin reaction (e.g. rash), flushing
Very rare: angioedema, Stevens-Johnson- Syndrome
Not known: exfoliative dermatitis
General disorders and administration site conditions:
Severe hypotensive responses have been reported for organic nitrates and include nausea, vomiting, restlessness, pallor and excessive perspiration.
During treatment with these tablets, a temporary hypoxaemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Particularly in patients with coronary artery disease this may lead to a myocardial hypoxia.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
• Fall of blood pressure ≤ 90mm Hg, paleness, sweating, weak pulse, tachycardia, light-headedness on standing, headache, weakness, dizziness, nausea and vomiting
• During isosorbide monintrate biotransformation nitrite ions are released, which may include methaemoglobinaemia and cyanosis with subsequent tachypnoea, anxiety, loss of consciousness and cardiac arrest. It can not be excluded that an overdose of isosorbide dinitrate may cause this adverse reaction.
• In very high doses the intracranial pressure may be increased. This might lead to cerebral symptoms.
• Stop intake of the drug
• General procedures in the event of nitrate-related hypotension:
- Patient should be kept horizontal with the head lowered and legs raised
- Supply oxygen
- Expand plasma volume
- For specific shock treatment admit patient to intensive care unit
• Raising the blood pressure if the blood pressure is very low
• Treatment of methaeglobinaemia
- Reduction therapy of choice with vitamin C, methylene-blue, or toluidine-blue
- Administer oxygen (if necessary)
- Initiate artificial ventilation
- Hemodialysis (of necessary)
• Resuscitation measures:
In case of signs of respiratory and circulatory arrest, initiate resuscitation measures immediately.
Pharmacotherapeutic group: Vasodilators used in cardiac dieases, organic nitrates, ATC Code: C01D A08
Isosorbide dinitrate causes a relaxation of vascular smooth muscle thereby inducing a vasodilation.
Both peripheral arteries and veins are relaxed by isosorbide dinitrate. The latter effect promotes venous pooling of blood and decreases venous return to the heart, thereby reducing ventricular end-diastolic pressure and volume (preload).
The action on arterial, and at higher dosages arteriolar vessels, reduce the systemic vascular resistance (afterload). This in turn reduces the cardiac work.
The effects on both preload and afterload lead subsequently to a reduced oxygen consumption of the heart.
Furthermore, isosorbide dinitrate causes redistribution of blood flow to the subendocardial regions of the heart when the coronary circulation is partially occluded by arteriosclerotic lesions. This last effect is likely to be due to a selective dilation of large coronary vessels. Nitrate-induced dilation of collateral arteries can improve the perfusion of poststenotic myocardium. Nitrates also dilate eccentric stenoses as they can counteract possible constricting factors acting on the residual arch of compliant smooth muscle at the site of the coronary narrowing. Furthermore, coronary spasms can be relaxed by nitrates.
Nitrates were shown to improve resting and exercise haemodynamics in patients suffering from congestive heart failure. In this beneficial effect several mechansims including an improvement of valvular regurgitation (due to the lessening of ventricular dilation) and the reduction of myocardial oxygen demand are involved.
By decreasing the oxygen demand and increasing the oxygen supply, the area of myocardial damage is reduced. Therefore, isosorbide dinitrate may be useful in selected patients who suffered a myocardial infarction.
Effects on other organ systems include a relaxation of the bronchial muscle, the muscles of the gastrointestinal, the biliary and the urinary tract. Relaxation of the uterine smooth muscles is reported as well.
Mechanism of action:
Like all organic nitrates, isosorbide dinitrate acts as a donor of nitric oxide (NO). NO causes a relaxation of vascular smooth muscle via the stimulation of guanylyl cyclase and the subsequent increase of intracellular cyclic guanosine monophosphate (cGMP) concentration. A cGMP-dependent protein kinase is thus stimulated, with resultant alteration of the phosphorylation of various proteins in the smooth muscle cell. This eventually leads to the dephosphorylation of the light chain of myosin and the lowering of contractility
After administration of one tablet of Isoket Retard 40 mean peak plasma concentrations of ISDN (8.0 ± 12 ng/ml) at 7.7 ± 2.9 hours and IS-5N (190 ± 33 ng/ml) at 8.7 ± 2.1 hours. The terminal half life of IS-5N which was least affected by the absorption process was 5.4 hours ± 0.5 sd.
Gastrointestinal absorption is slower than absorption through the oral mucosa. The first pass effect is higher when given orally. Isosorbide dinitrate is metabolized to isosorbide 2-mononitrate with a half-life of 2.01 h (±0.4 h) to 2.5 h and isosorbide 5-mononitrate with a half-life of 4.6 h (± 8 h). Both metabolites are pharmacologically active.
The relative bioavailability of Isoket Retard in comparison to the non-sustained-release tablet amounts to more than 80% after oral use.
No special precautions
Cartons of blister strips of polypropylene (PP) and aluminium or of PP/PP
Pack sizes 50, 56, 60, 84 and 90 tablets.
Only the pack sizes marked in bold are currently marketed.
No special precautions
Norgine Pharmaceuticals Limited
Norgine House, Widewater place, Moorhall Road,
Harefield, Middlesex, UB9 6NS, UK
Date of first authorisation: 25 November 1986
Date of latest renewal: 30 June 2008